Karen Bernstein - 17 Jun 2022 Form 4 Insider Report for Codiak BioSciences, Inc.

Role
Director
Signature
/s/ Yalonda Howze, Attorney-in-Fact for Karen Bernstein
Issuer symbol
N/A
Transactions as of
17 Jun 2022
Net transactions value
$0
Form type
4
Filing time
21 Jun 2022, 16:48:27 UTC
Previous filing
12 Apr 2022
Next filing
21 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CDAKQ Stock Option (Right to Buy) Award $0 +7,500 $0.000000 7,500 17 Jun 2022 Common Stock 7,500 $2.83 See footnote F1, F4
transaction CDAKQ Restricted Stock Units Award $0 +1,500 $0.000000 1,500 17 Jun 2022 Common Stock 1,500 See footnote F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders.
F2 Each restricted stock unit represents a contingent right to receive one share of common stock.
F3 On June 17, 2022, David Flores and Karen Bernstein Trust Agreement was granted 1,500 restricted stock units, which shall vest in full upon the earlier to occur of (i) June 17, 2023 and (ii) the Issuer's next annual meeting of stockholders.
F4 The reporting person is a trustee of David Flores and Karen Bernstein Trust Agreement.